1. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis
- Author
-
Gwang Ha Kim, Myung-Gyu Choi, Jin Il Kim, Soo Teik Lee, Hoon Jai Chun, Kook Lae Lee, Suk Chei Choi, Jae-Young Jang, Yong Chan Lee, Jae Gyu Kim, Ki Bae Kim, Ki-Nam Shim, Chong Il Sohn, Sung Kook Kim, Sang Gyun Kim, Jin Seok Jang, Nayoung Kim, Hwoon-Yong Jung, Hyojin Park, Kyu Chan Huh, Kwang Jae Lee, Su Jin Hong, Song Baek, Jin Joo Han, and Oh Young Lee
- Subjects
fexuprazan ,gastritis ,phase iii clinical trial ,potassium-competitive acid blocker ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background/Aims: Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chronic gastritis.Methods: In this study, 327 patients with acute or chronic gastritis who had one or more gastric erosions on endoscopy and subjective symptoms were randomized into three groups receiving fexuprazan 20 mg once a day (q.d.), fexuprazan 10 mg twice a day (b.i.d.), or placebo for 2 weeks. The posttreatment assessments were the primary endpoint (erosion improvement rate), secondary endpoints (cure rates of erosion and edema and improvement rates of redness, hemorrhage, and subjective symptoms), and drug-related adverse events.Results: Among the patients, 57.8% (59/102), 65.7% (67/102), and 40.6% (39/96) showed erosion improvement 2 weeks after receiving fexuprazan 20 mg q.d., fexuprazan 10 mg b.i.d., and placebo, respectively. Both fexuprazan 20 mg q.d. and 10 mg b.i.d. showed superior efficacy to the placebo (p=0.017 and p
- Published
- 2023
- Full Text
- View/download PDF